CurrentAmeriHealth CaritasPolicy CCP.1320

Endovenous stents

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1320 alerts

Get alerted when Policy CCP.1320 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage criteria and evidence summary for placement of endovenous (venous) stents for management of chronic venous disease and other venous obstructions; intended for AmeriHealth Caritas coverage determinations and providers seeking authorization guidance.

Policy Summary

PayerAmeriHealth Caritas

PolicyEndovenous stents

Policy CodePolicy CCP.1320

Change TypeNo material change

Effective DateSep 1, 2025

Last ReviewSep 1, 2025

Next Review DateJan 1, 2027

Key ActionObtain prior authorization that documents failed conservative management, objective symptoms, and imaging/procedural evidence of venous obstruction before stent placement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5iliac vein stents listed

97.6%procedural success

≈1,500patients in review

~20refs listed

2017–2025

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmeriHealth CaritasPolicy CCP.1320

Endovenous stents

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1320 alerts

Get alerted when Policy CCP.1320 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas

PolicyEndovenous stents

Policy CodePolicy CCP.1320

Change TypeNo material change

Effective DateSep 1, 2025

Last ReviewSep 1, 2025

Next Review DateJan 1, 2027

Key ActionObtain prior authorization that documents failed conservative management, objective symptoms, and imaging/procedural evidence of venous obstruction before stent placement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5iliac vein stents listed

97.6%procedural success

≈1,500patients in review

~20refs listed

2017–2025

Coverage Criteria for Endovenous Stent Placement

Covered indications for endovenous stent placement

Placement of endovenous stents for chronic venous disease management is clinically proven and may be necessary when ALL of the following are met:

Main criteria: Conservative management has failed to improve the condition

Conservative therapies include compression, dressings, pharmacologic therapy, physiotherapy; see documentation requirements for specifics

Angioplasty relationship: Either: a) Following a suboptimal or failed percutaneous transluminal angioplasty, as determined by the physician; OR b) As a planned adjunct to angioplasty when angioplasty alone is not expected to provide a durable result

Physician judgment required to document failed or inadequate angioplasty or rationale for planned adjunct

Symptomatic venous obstruction

Covered venous conditions: Iliac vein compression syndrome (May-Thurner/Cockett); Iliocaval or iliofemoral obstruction; Superior or inferior vena caval thrombosis; Post-thrombotic syndrome; Adjunct to catheter-directed thrombolysis for acute femoroiliocaval deep vein thrombosis; Post-radiation venous stenosis; Symptomatic post-traumatic venous stenosis; Salvage of thrombosed or stenotic symptomatic arteriovenous dialysis access; Thrombotic obstruction of major hepatic veins (Budd-Chiari syndrome); Transvenous decompression of portosystemic shunts; Post-operative stenosis related to congenital cardiac disease repair; Pulmonary vein stenosis from various causes
Any one of these conditions may satisfy the covered-indication requirement when the above main criteria are met

Summary: All elements above (failed conservative management; angioplasty relationship; and presence of at least one covered venous condition causing severe symptoms) must be satisfied for coverage consideration of endovenous stent placement.

See policy limitations for scenarios considered investigational or not medically necessary

Placement of an endovenous stent in the absence of objective-related symptoms or a functional limitation is specifically identified as a limitation of coverage. The policy notes that stenting a vein solely for anatomic findings without corresponding clinical symptoms may be considered investigational and not medically necessary. Additional cautions that may prompt denial include stenting in the setting of local or systemic infection (except in unusual circumstances), use of devices without U.S. Food and Drug Administration approval, stenting of popliteal or tibial veins, and stenting when the measured stenosis is ≤50% or when residual stenosis after angioplasty is <30%.

The policy includes a references section listing clinical studies, systematic reviews, guideline statements, and regulatory resources relevant to venous stenting. These reference entries do not themselves state additional coverage exclusions or modify the coverage criteria; they are provided to support clinical context and rationale.

Per the limitations text, endovenous stenting is considered investigational and not medically necessary for indications not listed as covered. Examples called out include stenting without objective symptoms or functional impairment, stenting in infected fields (except unusual circumstances), use of non‑FDA‑approved stents, popliteal or tibial vein stenting, venous stenosis ≤50%, residual stenosis <30% after angioplasty, and stenting for idiopathic intracranial hypertension.

The cited reference sections reproduced in the document are bibliographic only and do not contain explicit language stating additional ‘not medically necessary’ determinations beyond those summarized in the policy limitations.

Provider Requirements and Operational Guidance

Prior Authorization

Prior authorization required — demonstrate criteria met and alternatives attempted

Prior authorization is expected for endovenous stent placement and must document that all coverage criteria are met and that alternatives or conservative therapies were attempted (for example: compression therapy, dressings, pharmacologic treatment, physiotherapy, or percutaneous transluminal angioplasty alone) unless angioplasty is expected to be inadequate or stenting is adjunct to thrombolysis.

Show that conservative management has failed.
Document whether angioplasty was suboptimal/failed or that angioplasty alone is unlikely to provide a durable result.
Indicate the covered venous condition that justifies stenting (see covered indications).

Note

Prior authorization specifics and codes not listed in these chunks

This document section does not list specific prior authorization forms, operational requirements, or billing codes that are affected; providers should follow standard AmeriHealth Caritas prior authorization procedures and submit the clinical documentation described below.

Clinical Background and Rationale

Chronic venous disease represents long‑standing morphological and functional abnormalities of the venous system that produce symptoms such as pain, edema, skin changes, and ulceration. It can result from reflux, obstruction, or a combination of pathologies and—when advanced—produces persistent ambulatory venous hypertension leading to significant morbidity. Venous stenosis commonly arises from intimal hyperplasia and fibrosis related to prior thrombosis, indwelling central catheters or pacemaker leads, radiation, trauma, or extrinsic compression. Endovenous stents are synthetic tubular devices implanted percutaneously to provide radial mechanical support and restore venous patency in appropriately selected patients, typically reserved for disabling symptoms that have not responded to conservative measures.

Key Definitions

Endovenous stent — definition

DefinitionA synthetic tubular structure implanted in native or graft venous vasculature to provide mechanical radial support and enhance vessel patency.

DeliveryDelivered percutaneously, typically with angioplasty and imaging (eg, ultrasound) guidance and expanded by balloon or self-expanding mechanisms.

PurposeProvides radial support to restore or maintain luminal diameter and improve venous outflow in stenotic or occluded segments.

Device typesHistorically used arterial stents off‑label; dedicated venous stents have been developed to address arterial-stent limitations.

Regulatory noteMultiple iliac vein stents are commercially available in the US under premarket approval (eg, Wallstent, Vici, Venovo, Abre, Zilver Vena).

Chronic venous disease / chronic venous insufficiency — definition

Coding and Billing

Coverage-related coding notesmixed

The policy states that placement of endovenous stents for indications not listed as covered is investigational/not medically necessary, and enumerates specific limitations (stenting without objective symptoms, stenting in presence of infection except unusual circumstances, use of non‑FDA approved stents, stenting of popliteal or tibial veins, venous stenosis ≤50% or residual stenosis <30% after angioplasty, and venous stenting for idiopathic intracranial hypertension). The document does not list explicit billing or procedure codes in this section.

Policy Revision History

2017policy_update

Policy update recorded as part of document revision history covering 2017–2025 timeframe.

2023-06-19reference_update

FDA Premarket Approval database (PMA) was searched using product code QAN; database last updated June 19, 2023, and is cited in references.

2025-09-01policy_effective_dateLatest

Policy Summary

PayerAmeriHealth Caritas

PolicyEndovenous stents

Policy CodePolicy CCP.1320

Change TypeNo material change

Effective DateSep 1, 2025

Last ReviewSep 1, 2025

Next Review DateJan 1, 2027

Key ActionObtain prior authorization that documents failed conservative management, objective symptoms, and imaging/procedural evidence of venous obstruction before stent placement.

SourceLink

On This Page

Step Therapy

Conservative therapy first — attempt non‑stent measures prior to stenting

Conservative therapies should be tried before stent placement unless angioplasty is expected to be inadequate or stenting is planned as an adjunct to thrombolysis; examples of conservative measures include compression therapy, dressings, pharmacologic treatment, physiotherapy, and consideration of percutaneous transluminal angioplasty alone.

Compression therapy, dressings, physiotherapy/leg elevation/massage.
Pharmacologic treatment and wound care (dressings) for venous ulcers.
Percutaneous transluminal angioplasty alone may be appropriate before stenting.

Step Therapy

No step therapy program specified in these sections

No formal step therapy protocol or mandated stepwise approval pathway is described in the reference and update sections of this policy.

Although conservative therapies are expected before stenting, the policy does not specify a named step-therapy program or required timeframes.

Documentation Required

Required clinical documentation to support approval

Providers must supply clinical documentation demonstrating failed conservative management, objective symptoms or functional limitation, imaging or procedural evidence of venous obstruction and degree of stenosis, and the prior angioplasty status (suboptimal/failed or expected insufficiency) to support medical necessity.

Evidence that conservative management failed.
Objective symptoms or functional limitation attributable to the venous lesion.
Imaging/procedural documentation of venous obstruction and measured stenosis.
Documentation of prior angioplasty outcome or rationale for adjunctive stenting.

Documentation Required

Documentation of device approval and clinical rationale (references available)

Include references to device approval and clinical rationale where applicable; the policy cites FDA Premarket Approval database searches and multiple guideline and systematic review references that may support documentation of device approvals and indications.

If relevant, provide device identifiers and FDA PMA information (PMA database product code searches noted).
Cite applicable guideline or systematic review evidence referenced in the policy to justify the indication.

Denial Risk

Denial risk — investigational or not‑listed indications will be denied

Stenting for indications not listed as covered may be considered investigational and subject to denial; examples include stenting in veins without objective symptoms or functional limitation, stenting in the presence of infection (except unusual circumstances), use of non‑FDA approved stents, stenting of popliteal or tibial veins, venous stenosis ≤50% or residual stenosis <30% after angioplasty, and stenting for idiopathic intracranial hypertension.

Do not submit authorization for stenting when there is no objective symptom or functional limitation.
Avoid stenting for stenosis ≤50% or residual stenosis <30% post-angioplasty; these scenarios may be denied.
Use FDA‑approved devices; non‑approved stents are listed as investigational and may be denied.

Note

References listed here do not provide additional explicit denial language

The reference list section includes citations and FDA PMA database references but does not itself state operational denial triggers; providers should rely on the policy limitations for denial criteria rather than the references section alone.

DefinitionLong‑duration morphological and functional abnormalities of the venous system that produce symptoms or signs indicating the need for investigation or care.

Clinical spectrumIncludes chronic venous insufficiency as more advanced lower‑extremity disease characterized by persistent ambulatory venous hypertension causing pain, edema, skin changes, and ulceration.

EpidemiologyAffects more than six million U.S. adults.

Pathophysiology noteVenous stenosis arises from intimal hyperplasia and fibrosis and commonly affects central and upper‑extremity veins; causes include central catheters, pacemaker leads, dialysis catheters, prior radiation, trauma, or extrinsic compression.

Endovenous stenting — definition

DefinitionPlacement of intravascular metallic stents in venous segments (eg, iliofemoral veins, inferior vena cava) to treat venous outflow obstruction, chronic venous insufficiency, or sequelae of thrombosis.

Indications referencedApplied for iliofemoral/ilio‑caval obstruction, iliac vein compression (May‑Thurner), post‑thrombotic syndrome, adjunct to catheter‑directed thrombolysis, venous stenosis from radiation or trauma, salvage of dialysis access, Budd‑Chiari syndrome, and others as discussed in guidance and reviews.

TechniqueTypically performed endovascularly with angioplasty and image guidance; stents may be balloon‑expandable or self‑expanding and may be dedicated venous devices.

Evidence sourcesDescribed in systematic reviews, meta‑analyses, and society position statements cited in the references (eg, StatPearls review, Circulation, J Vasc Interv Radiol, Eur J Vasc Endovasc Surg).

Current policy effective and last reviewed on 2025-09-01 per document metadata.